In 2023, the FDA added BPC-157 to its “bulk drug substances” watchlist and started systematically pressuring compounding pharmacies to stop making it. In 2024, they expanded the squeeze to include a growing list of peptides that millions of Americans were using safely through licensed compounding pharmacies with doctor prescriptions. By 2025, the crackdown accelerated. Pharmacies shut down peptide production lines. Doctors stopped prescribing compounds they’d used successfully for years. Patients lost access to therapies that were improving their lives.
Nobody died from compounded BPC-157. Nobody was hospitalized from properly prescribed PT-141 or CJC-1295. There was no safety crisis. There was no wave of adverse events. The FDA moved against these compounds not because they were hurting people, but because they were helping people — outside the pharmaceutical industry’s profit model.
Follow the Money
This isn’t complicated. Peptide therapies administered through compounding pharmacies cost patients $50-200 per month. If a pharmaceutical company develops a patented peptide drug through the FDA approval process, that same therapy will cost $1,000-5,000 per month. The FDA’s regulatory framework doesn’t just protect safety — it protects the economic model that makes pharmaceutical companies billions.
I’m not saying drug safety testing has no value. Phase III clinical trials serve a purpose. But when a compound like BPC-157 has been studied in hundreds of published papers, has been used by hundreds of thousands of people through legitimate medical channels with an excellent safety record, and the FDA’s response is to restrict access rather than facilitate proper research — something else is driving the decision.
The revolving door between the FDA and pharmaceutical companies is well-documented. Senior FDA officials routinely leave the agency for high-paying positions at the companies they previously regulated. The incentive structure is broken at a fundamental level. Regulatory agencies that are supposed to protect public health instead protect market monopolies.
What We Lost
Let me tell you about real people who were affected by this crackdown.
A 55-year-old veteran with chronic joint pain from decades of service who was using BPC-157 to manage inflammation and avoid opioid painkillers. His compounding pharmacy stopped making it. His options now? Go back to NSAIDs that are destroying his gut lining, or accept a prescription for opioids that we all know are actually dangerous. The FDA “protected” him right back into the drugs that kill 80,000 Americans a year.
A woman in her 40s using PT-141 to address sexual dysfunction that SSRIs caused. Her doctor prescribed it through a compounding pharmacy at a fraction of what the branded version costs. Access removed. She can either pay 10x more for the branded pharmaceutical product or go without a therapy that was working.
Athletes and fitness enthusiasts using TB-500 for injury recovery — healing tendons and ligaments faster, getting back to training, staying healthy. These aren’t drug abusers. These are people taking proactive responsibility for their own physical recovery. And the FDA wants to make that harder.
The Bodily Autonomy Argument
I’ve always believed that what you put in your own body is your business. Period. Full stop. A government that can dictate what substances you’re allowed to use for your own health optimization has too much power over your life.
I’ve been open about my own use of peptides, SARMs, hormones, and research compounds for years. I publish my bloodwork. I discuss side effects honestly when they occur. I don’t hide behind fake natty claims or pretend that everything I use is risk-free. This transparency is exactly what harm reduction looks like.
The FDA’s approach is the opposite of harm reduction. By restricting access to compounds through legitimate medical channels — where dosing is precise, purity is verified, and physician oversight exists — they push people toward unregulated gray-market vendors. When you can’t get pharmaceutical-grade BPC-157 from a compounding pharmacy with a prescription, you order research-grade powder from an overseas vendor with unknown purity. The FDA’s “safety” measures make the actual safety situation worse.
This is the same failed logic that drives drug prohibition. Making something harder to access through legal channels doesn’t eliminate demand — it just makes the supply chain more dangerous.
Living in Thailand Changed My Perspective
Part of the reason I’m based in Pattaya is the regulatory environment. In Thailand, I can walk into a pharmacy and purchase many compounds that require prescriptions or are restricted entirely in the US. This isn’t because Thailand is reckless with health regulation — they have their own standards and oversight. It’s because their regulatory philosophy treats adults as capable of making informed decisions about their own health.
The result? People here have access. They can optimize their health without navigating a Byzantine regulatory system designed to funnel them toward the most expensive treatment options. Expats and medical tourists come to Thailand specifically because they can access therapies that their home countries have restricted — not because those therapies are dangerous, but because the economic and regulatory structures back home have made them artificially scarce.
Does greater access mean some people make bad decisions? Sure. But that’s true of literally everything — alcohol, driving, financial investing. We don’t ban all investment because some people make bad trades. We provide information and let adults make choices. Health optimization should work the same way.
What Needs to Change
Compounding pharmacy protections: Congress needs to explicitly protect the right of licensed compounding pharmacies to produce peptides and other compounds when prescribed by a licensed physician. The FDA’s administrative creep into this space through reinterpretation of existing regulations — rather than new legislation — is an end-run around democratic oversight.
Fast-track pathways for well-studied compounds: BPC-157 has hundreds of published studies. Requiring a pharmaceutical company to spend $2 billion on Phase III trials for a compound that can’t be patented (and therefore can’t generate the returns to justify that investment) is a structural failure. We need a regulatory pathway for well-studied, non-patentable compounds that reflects the existing evidence base rather than treating them like novel drugs. This is a direct application of the Tony Huge Laws of Biochemistry Physics—the therapeutic potential of a molecule exists independently of the economic model used to deliver it. Restricting access based on patentability is a violation of biochemical reality.
Harm reduction framework: Instead of restricting access, provide information. Mandatory lab testing standards for peptide vendors. Required certificates of analysis. Education resources for physicians and patients. Make the safe path the easy path, instead of making it harder to do the right thing.
Conflict of interest reform: Close the revolving door between FDA and pharma. Lifetime bans on FDA officials taking positions at companies they regulated. Independent funding for the review process that doesn’t come from the companies being reviewed. The current system is structurally corrupt, and everyone involved knows it.
The Bigger Picture
The fight over peptide access is really a fight about who controls your biology. Do you own your body, or does the government get veto power over what you’re allowed to do with it? Can a 50-year-old man decide with his doctor that BPC-157 is worth trying for his chronic tendon issues, or does a bureaucrat in Washington get to override that decision?
I know where I stand. I’ve stood here publicly for years, and I’ve paid real costs for that stance — legal battles, business disruptions, and personal attacks from people who think the government should be the gatekeeper of your health choices.
But I’ve also seen the other side. I’ve seen what happens when people have access to the full spectrum of optimization tools and the information to use them wisely. They get healthier. They recover faster. They age better. They take control of their own lives in a way that the current system actively discourages.
That’s worth fighting for. And no amount of FDA enforcement actions is going to change my position on that.
Interesting Perspectives
The FDA’s regulatory posture on peptides isn’t just a health policy issue; it’s a philosophical battleground with implications for human enhancement and economic freedom. Some legal scholars frame this as a “right to repair” for the human body—if you own a car, you can modify it; why not your own biology? This perspective views the body as the ultimate piece of personal property, and regulatory overreach as a form of trespass. Others point to the rise of “biohacking” communities and direct-to-consumer lab testing as evidence of a growing civil disobedience movement against centralized medical authority. People are self-experimenting and sharing data in decentralized networks, effectively creating parallel, crowd-sourced clinical trials that bypass traditional gatekeepers. Furthermore, the crackdown on peptides is seen by some as a precursor to future battles over more advanced regenerative therapies like exosomes, where the profit motives of large institutions will again clash with individual access. The underlying tension is between a paternalistic model that prioritizes risk elimination and an empowerment model that accepts some risk in exchange for autonomy and accelerated innovation.
Citations & References
- U.S. Food and Drug Administration. (2023). Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act. FDA.gov. [This is the official notice placing BPC-157 on the watchlist, demonstrating the regulatory action.]
- Lichtblau, E. (2012). F.D.A. and Industry: A Gap in Views on Drug Safety. The New York Times. [Documents the well-documented revolving door and differing priorities between regulators and pharma.]
- Centers for Disease Control and Prevention. (2023). Drug Overdose Deaths in the United States, 2001–2021. CDC.gov. [Provides data on the ~80,000 annual opioid overdose deaths, highlighting the dangers of the “approved” alternatives patients are forced back to.]
- U.S. Government Accountability Office. (2022). DRUG COMPOUNDING: FDA Has Taken Steps to Implement Compounding Law, but Some States and Stakeholders Reported Challenges. GAO.gov. [A government report detailing the ongoing tensions and challenges between the FDA and compounding pharmacies.]
- Downing, N. S., et al. (2017). Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. JAMA. [Study showing a significant portion of FDA-approved drugs later have serious safety issues, questioning the infallibility of the standard approval pathway.]
Related Articles
- Ipamorelin: The Cleanest Growth Hormone Peptide You’re Not Using Correctly
- Exosome Therapy: The Regenerative Anti-Aging Breakthrough Hiding in Plain Sight
- Testosterone Optimization: The Enhanced Man’s Foundational Protocol
- Natural Testosterone Optimization: Boost T Levels Without TRT
- Vilon Bioregulator: The Soviet-Era Immune Peptide Powering Longevity
Frequently Asked Questions
Is BPC-157 legal to buy in 2024?
BPC-157 exists in a legal gray area. While not FDA-approved for human use, it was available through compounding pharmacies with prescriptions. However, the FDA's 2023 crackdown on bulk drug substances has pressured many pharmacies to stop compounding it. Legal status varies by state and pharmacy, so consult a healthcare provider about current availability.
Why is the FDA banning peptides?
The FDA targets peptides lacking approved therapeutic claims, viewing them as unapproved drugs. The agency argues safety concerns justify restricting compounding pharmacy access. Critics contend the crackdown limits patient autonomy and access to substances used safely under medical supervision, prioritizing regulatory control over individual choice.
Can I still get peptides from compounding pharmacies?
Peptide availability through compounding pharmacies has significantly declined due to FDA pressure. Some pharmacies continue offering specific peptides with valid prescriptions, but options are increasingly limited. The regulatory landscape continues shifting, making it essential to work with knowledgeable healthcare providers familiar with current restrictions.